Hak-Kim Chan Selected Research

Powders

10/2022	Preparation and Characterization of Inhalable Ivermectin Powders as a Potential COVID-19 Therapy.
4/2022	A dual action of D-amino acids on anti-biofilm activity and moisture-protection of inhalable ciprofloxacin powders.
3/2021	Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.
1/2021	Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.
12/2020	Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections.
8/2020	Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells.
5/2020	Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization.
10/2019	High Resolution Nanoscale Probing of Bacteriophages in an Inhalable Dry Powder Formulation for Pulmonary Infections.
9/2019	Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
1/2018	Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hak-Kim Chan Research Topics

Disease

37	Infections 07/2022 - 01/2010
19	Respiratory Tract Infections (Respiratory Tract Infection) 07/2022 - 05/2015
8	Bacterial Infections (Bacterial Infection) 04/2022 - 01/2016
8	Cystic Fibrosis (Mucoviscidosis) 01/2021 - 06/2010
8	Asthma (Bronchial Asthma) 01/2020 - 10/2003
6	Tuberculosis (Tuberculoses) 01/2018 - 02/2013
4	COVID-19 10/2022 - 01/2021
4	Wound Infection (Wound Infections) 08/2022 - 01/2020
4	Wounds and Injuries (Trauma) 08/2021 - 01/2019
4	Inflammation (Inflammations) 01/2021 - 05/2015
4	Lung Diseases (Lung Disease) 06/2020 - 11/2010
4	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 01/2005
4	Neoplasms (Cancer) 01/2020 - 11/2010
4	Respiratory Tract Diseases (Respiratory Tract Disease) 12/2019 - 03/2015
4	Pneumonia (Pneumonitis) 01/2017 - 04/2014
3	Cough 01/2020 - 06/2004
2	Lung Neoplasms (Lung Cancer) 01/2021 - 08/2015
2	Ventilator-Associated Pneumonia 07/2018 - 01/2018
2	Communicable Diseases (Infectious Diseases) 03/2018 - 03/2015
2	Critical Illness (Critically Ill) 01/2018 - 10/2016
2	Human Influenza (Influenza) 02/2016 - 03/2015
2	Bronchiectasis 01/2016 - 05/2015
1	Weight Gain 11/2021
1	Urinary Tract Infections (Urinary Tract Infection) 01/2021
1	Catheter-Related Infections 01/2021
1	Pseudomonas Infections 12/2020
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2020
1	Pulmonary Aspergillosis 04/2019
1	Smoke Inhalation Injury 01/2018
1	Body Weight (Weight, Body) 11/2017
1	Cryptosporidiosis 10/2017
1	Autoimmune Diseases (Autoimmune Disease) 02/2016
1	Gram-Negative Bacterial Infections 02/2016

Drug/Important Bio-Agent (IBA)

28	Anti-Bacterial Agents (Antibiotics)IBA 04/2022 - 01/2010
17	Pharmaceutical PreparationsIBA 01/2022 - 02/2013
15	PowdersIBA 10/2022 - 09/2005
12	AerosolsIBA 04/2022 - 11/2010
9	Ciprofloxacin (Cipro)FDA LinkGeneric 12/2020 - 06/2010
9	Mannitol (Osmitrol)FDA LinkGeneric 01/2016 - 10/2003
7	Colistin (Coly-Mycin)FDA Link 08/2020 - 08/2015
5	rifapentine (Priftin)FDA Link 01/2017 - 05/2014
4	Antiviral Agents (Antivirals)IBA 10/2022 - 03/2015
4	Polymyxins (Polymyxin)IBA 02/2022 - 02/2016
4	Small Interfering RNA (siRNA)IBA 12/2019 - 01/2012
3	Peptides (Polypeptides)IBA 01/2022 - 03/2015
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2020 - 10/2003
3	Tobramycin (Nebcin)FDA LinkGeneric 12/2018 - 09/2013
3	SteroidsIBA 04/2014 - 10/2003
2	Ivermectin (Mectizan)FDA Link 10/2022 - 05/2022
2	Anti-Infective Agents (Microbicides)IBA 04/2022 - 06/2020
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 08/2021 - 01/2021
2	HydrogelsIBA 08/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 06/2020 - 01/2011
2	Liposomes (Liposome)IBA 01/2020 - 01/2020
2	Budesonide (Pulmicort)FDA LinkGeneric 01/2018 - 06/2004
2	Histamine (Histamine Dihydrochloride)FDA Link 12/2003 - 10/2003
1	Lactose FDA LinkGeneric 10/2022
1	SolutionsIBA 01/2022
1	BuffersIBA 11/2021
1	Phosphates (Orthophosphate)IBA 11/2021
1	TabletsIBA 11/2021
1	Investigational DrugsIBA 08/2021
1	Biological ProductsIBA 01/2021
1	CRISPR-Associated Protein 9IBA 01/2021
1	Salmeterol Xinafoate (Serevent)FDA Link 01/2020
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2020
1	Fluticasone (Cutivate)FDA LinkGeneric 01/2020
1	Excipients (Suspending Agents)IBA 01/2020
1	Antifungal AgentsIBA 04/2019
1	Glutathione (Reduced Glutathione)IBA 01/2019
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2019
1	Clarithromycin (Biaxin)FDA LinkGeneric 12/2018
1	Protein Isoforms (Isoforms)IBA 03/2018
1	Tuberculosis VaccinesIBA 01/2018
1	SuspensionsIBA 01/2018
1	Clofazimine (Lamprene)FDA Link 10/2017
1	Polymyxin B (Aerosporin)FDA LinkGeneric 01/2017
1	Blood Proteins (Serum Proteins)IBA 01/2017
1	Capsules (Microcapsules)IBA 01/2017
1	Zanamivir (Relenza)FDA Link 02/2016
1	Dosage Forms (Dosage Form)IBA 01/2016
1	Leucine (L-Leucine)FDA Link 01/2016
1	AntigensIBA 01/2016
1	Biomarkers (Surrogate Marker)IBA 01/2016
1	Silk FDA Link 08/2015
1	Drug CarriersIBA 08/2015
1	MacrolidesIBA 05/2015
1	Expectorants (Mucolytics)IBA 05/2015
1	Gatifloxacin (Zymar)FDA Link 04/2015
1	Ambroxol (Mucosolvan)IBA 04/2015
1	GATIBA 04/2015

Therapy/Procedure

21	Therapeutics 10/2022 - 06/2004
11	Phage Therapy 08/2022 - 01/2016
7	Nebulizers and Vaporizers (Inhaler) 10/2022 - 11/2010
5	Dry Powder Inhalers 05/2015 - 01/2010
3	Oral Administration 10/2022 - 01/2020
2	Respiratory Therapy (Therapy, Respiratory) 08/2020 - 01/2016
2	Drug Therapy (Chemotherapy) 05/2015 - 05/2015
1	Mechanical Ventilators (Ventilator) 02/2016
1	Critical Care (Surgical Intensive Care) 02/2016